Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials? (English)
- New search for: Fountzilas, C.
- New search for: Stuart, S.
- New search for: Hernandez, B.
- New search for: Bowhay-Carnes, E.
- New search for: Michalek, J.
- New search for: Sarantopoulos, J.
- New search for: Karnad, A.
- New search for: Patel, S.
- New search for: Weitman, S.
- New search for: Mahalingam, D.
- New search for: Fountzilas, C.
- New search for: Stuart, S.
- New search for: Hernandez, B.
- New search for: Bowhay-Carnes, E.
- New search for: Michalek, J.
- New search for: Sarantopoulos, J.
- New search for: Karnad, A.
- New search for: Patel, S.
- New search for: Weitman, S.
- New search for: Mahalingam, D.
In:
INVESTIGATIONAL NEW DRUGS
;
35
, 3
;
386-391
;
2017
-
ISSN:
- Article (Journal) / Print
-
Title:Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
-
Contributors:Fountzilas, C. ( author ) / Stuart, S. ( author ) / Hernandez, B. ( author ) / Bowhay-Carnes, E. ( author ) / Michalek, J. ( author ) / Sarantopoulos, J. ( author ) / Karnad, A. ( author ) / Patel, S. ( author ) / Weitman, S. ( author ) / Mahalingam, D. ( author )
-
Published in:INVESTIGATIONAL NEW DRUGS ; 35, 3 ; 386-391
-
Publisher:
- New search for: Springer Science + Business Media
-
Publication date:2017-01-01
-
Size:6 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 615.1
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 615.1 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 35, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 251
-
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machineryJiang, J. / Lu, Y. / Li, Z. / Li, L. / Niu, D. / Xu, W. / Liu, J. / Fu, L. / Zhou, Z. / Gu, Y. et al. | 2017
- 260
-
A truncated apoptin protein variant selectively kills cancer cellsRuiz-Martínez, S. / Castro, J. / Vilanova, M. / Bruix, M. / Laurents, D. V. / Ribó, M. / Benito, A. et al. | 2017
- 269
-
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective studyTakahara, N. / Isayama, H. / Nakai, Y. / Sasaki, T. / Ishigaki, K. / Saito, K. / Akiyama, D. / Uchino, R. / Mizuno, S. / Yagioka, H. et al. | 2017
- 277
-
State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261Föhr, K. J. / Knippschild, U. / Herkommer, A. / Fauler, M. / Peifer, C. / Georgieff, M. / Adolph, O. et al. | 2017
- 290
-
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumorsKyriakopoulos, C. E. / Braden, A. M. / Kolesar, J. M. / Eickhoff, J. C. / Bailey, H. H. / Heideman, J. / Liu, G. / Wisinski, K. B. et al. | 2017
- 298
-
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumorsForero, A. / Bendell, J. C. / Kumar, P. / Janisch, L. / Rosen, M. / Wang, Q. / Copigneaux, C. / Desai, M. / Senaldi, G. / Maitland, M. L. et al. | 2017
- 307
-
A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumorsMukai, H. / Kogawa, T. / Matsubara, N. / Naito, Y. / Sasaki, M. / Hosono, A. et al. | 2017
- 315
-
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumorsShapiro, G. I. / Vaishampayan, U. N. / LoRusso, P. / Barton, J. / Hua, S. / Reich, S. D. / Shazer, R. / Taylor, C. T. / Xuan, D. / Borghaei, H. et al. | 2017
- 324
-
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumorsFu, S. / Hirte, H. / Welch, S. / Ilenchuk, T. T. / Lutes, T. / Rice, C. / Fields, N. / Nemet, A. / Dugourd, D. / Piha-Paul, S. et al. | 2017
- 334
-
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II studySalgia, R. / Weaver, R. W. / McCleod, M. / Stille, J. R. / Yan, S. B. / Roberson, S. / Polzer, J. / Flynt, A. / Raddad, E. / Peek, V. L. et al. | 2017
- 345
-
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancerThomas, M. / Sadjadian, P. / Kollmeier, J. / Lowe, J. / Mattson, P. / Trout, J. R. / Gargano, M. / Patchen, M. L. / Walsh, R. / Beliveau, M. et al. | 2017
- 359
-
Current achievements and future perspectives of metronomic chemotherapyRomiti, A. / Falcone, R. / Roberto, M. / Marchetti, P. et al. | 2017
- 375
-
Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agentsPiska, K. / Koczurkiewicz, P. / Bucki, A. / Wójcik-Pszczoła, K. / Kołaczkowski, M. / Pękala, E. b. et al. | 2017
- 386
-
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?Fountzilas, C. / Stuart, S. / Hernandez, B. / Bowhay-Carnes, E. / Michalek, J. / Sarantopoulos, J. / Karnad, A. / Patel, S. / Weitman, S. / Mahalingam, D. et al. | 2017
- 392
-
Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experienceSasada, S. / Ushirozawa, N. / Kobayashi, N. / Fujiwara, Y. / Tamura, K. / Yamamoto, N. et al. | 2017
- 397
-
Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumorsFu, S. / Hirte, H. / Welch, S. / Ilenchuk, T. T. / Lutes, T. / Rice, C. / Fields, N. / Nemet, A. / Dugourd, D. / Piha-Paul, S. et al. | 2017